Skip to main content
. 2021 Jan 26;4(1):344–351. doi: 10.1021/acsptsci.0c00206

Figure 2.

Figure 2

In vivo complete blood counts after treatment with (A) escalating doses of [211At]MM4 4 weeks post-administration and (B) single dose of [211At]MM4 at 36 MBq/kg evaluated at 3, 7, 14, and 28 day time points displayed as violin plots for white blood cell subpopulations, lymphocytes and neutrophils (n = 4/group except n = 8/group control and 36MBq/kg dose level; asterisk (*) denotes statistical significance by one-way ANOVA analysis; p-value < 0.05).